22
Participants
Start Date
February 7, 2024
Primary Completion Date
March 25, 2026
Study Completion Date
March 25, 2026
EGCG 300 mg
"Participants will be administered EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
Placebo for EGCG 300 mg
"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
EGCG 600 mg
"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
Placebo for EGCG 600 mg
"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
NOT_YET_RECRUITING
University of Virginia, Charlottesville
NOT_YET_RECRUITING
University of Michigan, Ann Arbor
RECRUITING
Massachusetts General Hospital, Boston
Collaborators (1)
Cornell University
OTHER
Massachusetts General Hospital
OTHER
University of Michigan
OTHER
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Hal Chapman
OTHER